ArticleJournal of hepatocellular carcinoma2026
Multimodal Modeling Distinguishes Treatment Response from Overall Survival in Hepatocellular Carcinoma Receiving Combined Interventional and Targeted Immunotherapy.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: While combined interventional therapies and targeted immunotherapy have improved outcomes for unresectable hepatocellular carcinoma (HCC), radiographic tumor shrinkage does not guarantee prolonged survival (the "responder paradox"). We hypothesized that these distinct endpoints may be associated with different clinical and biological factors and require separate predictive strategies. This study aimed to develop the predictive radiomics-integrated multimodal estimation (PRIME) system to independently predict and biologically characterize treatment response versus overall survival (OS). Methods: In this multicenter study comprising 246 patients receiving combined interventional therapies and targeted immunotherapy, we integrated clinical data and dual-phase CT radiomics. We employed multimodal fusion algorithms to construct two models: PRIME-R (predicting 3-month objective response) and PRIME-S (predicting OS). Model performance was rigorously tested in an external validation cohort. Furthermore, we utilized SHapley Additive exPlanations and matched imaging-transcriptomic data to elucidate the specific clinical and molecular features associated with each outcome. Results: The PRIME models demonstrated superior accuracy compared to single-modality approaches. In external validation, PRIME-R achieved an AUC of 0.85, while PRIME-S achieved a C-index of 0.72. Significant risk stratification was confirmed (HR = 3.31, 95% CI: 2.06-5.31, P < 0.001). Crucially, feature analysis revealed a distinct divergence: PRIME-R was primarily driven by tumor morphology. In contrast, PRIME-S relied heavily on systemic inflammation and liver function reserve. Transcriptomic profiling supported this interpretation, showing that response was associated with acute immune activation, whereas survival was associated with metabolic adaptation and tissue homeostasis. Conclusion: Short-term response and long-term survival in HCC are distinct clinical endpoints associated with different biological drivers. The PRIME system effectively distinguishes these outcomes, offering insights into the responder paradox and supporting dual-endpoint risk stratification pending further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.